Tislelizumab

Key takeaways

Tislelizumab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tislelizumab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tislelizumab from memory before moving on to harder problems.

Reference excerpt

Tislelizumab, sold under the brand name Tevimbra among others, is an anti-cancer medication used for the treatment of various forms of cancer. It is a humanized monoclonal antibody directed against programmed death receptor-1. It is being developed by BeOne Medicines. Tislelizumab was approved for medical use in China in December 2019, in the European Union in September 2023, in the United States in March 2024, and in Australia in May 2024.

Medical uses In China, tislelizumab is indicated to treat people with classical Hodgkin lymphoma who have received at least two prior therapies; and to treat people with locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within twelve months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. In the EU, tislelizumab is indicated for the treatment of adults with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy. In November 2024, the European Commission expanded the indication of tislelizumab for use alongside platinum- and fluoropyrimidine-based chemotherapy to treat people with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma; and, in combination with platinum-based chemotherapy, for those with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma. In the US, tislelizumab is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor; and, in combination with platinum and fluoropyrimidine-based chemotherapy, it is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.

Adverse effects Adverse effects include anemia, leukopenia, thrombocytopenia, nausea, increased aspartate transaminase (AST), neutropenia, fatigue, decreased appetite, vomiting, musculoskeletal pain, constipation, hypoproteinemia and rash. Fatal events such as respiratory infection or failure, and hepatic injury have been reported. Adverse events are more common when combined with chemotherapy.

Pharmacokinetics Phase I clinical trial from 2016 has results suggesting an elimination half-life of 11 to 17 days. A 2021 structural and functional analysis suggests a t1/2 of 238 ± 32 minutes, 30- to 80-times higher than pembrolizumab and nivolumab.

History Phase I trials began in the United States and Australia in June 2015. Some early results were announced in July 2016. A phase II clinical trial for urothelial cancer started in China in 2017. Tislelizumab "demonstrated efficacy and tolerability" in a multicenter phase III trial for advanced hepatocellular carcinoma started in January 2018. In November 2024, the European Medicines Agency expanded the indication of tislelizumab as part of a first-line combination treatment for adults with advanced gastric or esophageal cancer.

Society and culture

Names Tislelizumab is the international nonproprietary name.

References

Further reading Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, et al. (December 2023). "The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials". BMC Pulmonary Medicine. 23 (1): 495. doi:10.1186/s12890-023-02755-3. PMC 10704633. PMID 38066549. Liu S, Dou L, Li S (2024). "Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation". Therapeutic Advances in Gastroenterology. 17 17562848241233134. doi:10.1177/17562848241233134. PMC 10903196. PMID 38425370. Ntellas P, Chau I (January 2024). "Updates on Systemic Therapy for Hepatocellular Carcinoma". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 44 e430028. doi:10.1200/EDBK_430028. PMID 38175973.

External links "Tislelizumab-jsgr". National Cancer Institute. "Tislelizumab (Code C121775)". NCI Thesaurus. Clinical trial number NCT03430843 for "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Tislelizumab

Start with the simplest possible case. Write down what Tislelizumab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tislelizumab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tislelizumab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tislelizumab

In research: Tislelizumab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tislelizumab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tislelizumab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Cancer treatments, Monoclonal antibodies, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Tislelizumab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Tislelizumab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tislelizumab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tislelizumab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tislelizumab in simple terms?

Tislelizumab, sold under the brand name Tevimbra among others, is an anti-cancer medication used for the treatment of various forms of cancer. It is a humanized monoclonal antibody directed against programmed death receptor-1.

Why does Tislelizumab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tislelizumab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tislelizumab.